ORIGINAL RESEARCH PAPER
Volume - 15 | Issue - 07 | July - 2026 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

TUMOR MICROENVIRONMENT IN PROSTATE CANCER: IMMUNE INTERACTIONS, MACROPHAGE BIOLOGY, AND EMERGING THERAPEUTIC TARGETS

Pathology

Dr.s.Manisha* PGY 3*Corresponding Author

Dr. Ather fatima Professor

Dr Naval kishore bajaj HOD & Professor

ABSTRACT

Prostate cancer is one of the most common malignancies affecting men worldwide and remains a major cause of cancer-related mortality. In recent years, increasing evidence has demonstrated that tumor progression is significantly influenced by the tumor microenvironment. The prostate tumor microenvironment consists of stromal fibroblasts, inflammatory cells, endothelial cells, extracellular matrix proteins, cytokines, chemokines, and signaling mediators that interact continuously with tumor cells. Among immune cells present within this microenvironment, tumor-associated macrophages have emerged as important regulators of tumor progression. These cells contribute to angiogenesis, immune suppression, extracellular matrix remodeling, epithelial–mesenchymal transition, metastatic dissemination, and therapeutic resistance. Several studies have demonstrated increased macrophage infiltration in aggressive and metastatic prostate cancers, highlighting their potential prognostic significance. Recent advances in molecular oncology have identified important signaling pathways involved in macrophage recruitment and polarization, including STAT3, NOTCH, CSF-1/CSF-1R, NF-κB, and chemokine-mediated pathways. In addition, exosomal communication between tumor cells and immune cells has been recognized as an important mechanism driving immune modulation within the prostate cancer microenvironment. This review summarizes current understanding of tumor microenvironment biology in prostate cancer, emerging concepts regarding tumor-associated macrophages, and novel therapeutic strategies targeting inflammatory signaling pathways and immune cell interactions. Further studies are required to translate these findings into clinical practice.

KEYWORDS

Prostate Cancer, Tumor Microenvironment, Tumor-associated Macrophages, Inflammation, Immune Evasion, Immunotherapy.

INTRODUCTION

Prostate cancer remains one of the most frequently diagnosed malignancies among men and represents a significant global health burden. According to recent global cancer statistics, prostate cancer accounts for more than 1.4 million newly diagnosed cases annually and remains among the leading causes of cancer-related mortality in men. Despite advances in screening, molecular diagnostics, and targeted therapy, progression to advanced and metastatic disease continues to pose a major therapeutic challenge.[1]

Historically, prostate cancer was considered predominantly an androgen-dependent epithelial malignancy driven by genetic and hormonal alterations. However, contemporary research has demonstrated that tumor progression is strongly influenced by the surrounding tumor microenvironment. The tumor microenvironment is increasingly recognized as an active biological system capable of regulating tumor proliferation, angiogenesis, immune escape, invasion, and metastasis. Interactions between tumor cells and stromal components generate a complex inflammatory and immunosuppressive niche that facilitates tumor progression.[2]

Chronic inflammation within the tumor microenvironment promotes continuous tissue remodeling, cytokine production, angiogenesis, and immune dysregulation, all of which contribute to tumor survival and dissemination. Among immune cells infiltrating prostate tumors, macrophages constitute one of the most abundant and biologically important populations. Increased macrophage density has been associated with higher Gleason score, advanced pathological stage, extracapsular extension, biochemical recurrence, and metastatic disease.[3] [4] The growing recognition of tumor microenvironment biology has opened new avenues for therapeutic intervention, with current research increasingly focused on targeting inflammatory signaling pathways, macrophage polarization, stromal interactions, and immune checkpoints in prostate cancer.[5]

Tumor Microenvironment in Prostate Cancer

The prostate tumor microenvironment consists of neoplastic epithelial cells surrounded by fibroblasts, immune cells, endothelial cells, extracellular matrix proteins, and soluble inflammatory mediators. These components interact continuously through cytokine signaling, growth factor release, and extracellular vesicle-mediated communication. Cancer-associated fibroblasts represent one of the major stromal populations involved in tumor progression. These fibroblasts promote extracellular matrix remodeling and facilitate tumor invasion through secretion of matrix metalloproteinases, transforming growth factor-beta, and fibroblast growth factors.[6]

Hypoxia within rapidly growing tumors further alters the microenvironment by stimulating angiogenesis through vascular endothelial growth factor production. Hypoxic signaling also contributes to macrophage recruitment and development of an immunosuppressive milieu. Studies have demonstrated that prostate tumors with high inflammatory infiltration frequently exhibit increased resistance to therapy and greater metastatic potential, emphasizing the relationship between inflammation and tumor aggressiveness.[7]

Tumor-Associated Macrophages and Tumor Progression

Tumor-associated macrophages have emerged as central regulators of prostate cancer progression. Macrophages exhibit remarkable functional plasticity and may adopt distinct phenotypes depending on local cytokine signals. Classically activated macrophages possess antitumoral properties and participate in cytotoxic immune responses, whereas alternatively activated macrophages promote tumor progression through immunosuppressive and proangiogenic mechanisms.[8]

Several studies have demonstrated that increased macrophage infiltration correlates with higher Gleason score, advanced tumor stage, increased angiogenesis, extraprostatic extension, metastatic progression, and poor overall prognosis. Tumor-associated macrophages secrete numerous cytokines and growth factors including interleukin-10, transforming growth factor-beta, vascular endothelial growth factor, and matrix metalloproteinases. These mediators suppress cytotoxic T-cell activity while simultaneously promoting angiogenesis and extracellular matrix degradation.[9] [10] Recent evidence has additionally demonstrated that macrophages contribute significantly to epithelial–mesenchymal transition, a process associated with tumor invasion and metastatic dissemination.[11]

Molecular Pathways Driving Immune Modulation

Several molecular pathways regulate inflammatory signaling and macrophage polarization within the prostate cancer microenvironment. STAT3 activation promotes inflammatory cytokine production and contributes to macrophage-mediated immune suppression. Persistent STAT3 activation has been associated with aggressive tumor behavior and resistance to therapy. Similarly,

NOTCH signaling influences macrophage recruitment and maintenance of tumor-promoting inflammatory responses. Aberrant activation of NOTCH pathways has been implicated in progression of advanced prostate cancer.[12]

The CSF-1/CSF-1R signaling axis also plays a critical role in macrophage recruitment and survival. Increased CSF-1 signaling has been associated with enhanced inflammatory infiltration and poor prognosis. Chemokines released by tumor cells and stromal fibroblasts recruit inflammatory cells into tumor tissue and establish a chronic inflammatory microenvironment favoring tumor progression.[13]

Recent studies have additionally highlighted the importance of extracellular vesicles and exosomal signaling in communication between tumor cells and inflammatory cells. Exosomes are nanosized extracellular vesicles secreted by tumor cells that carry proteins, RNA, microRNA, and signaling molecules capable of altering immune cell behavior. Prostate cancer-derived exosomes modulate macrophage polarization, suppress antitumor immune responses, and facilitate metastatic dissemination.[14]

Therapeutic Implications

The growing understanding of tumor microenvironment biology has led to development of novel therapeutic approaches targeting inflammatory signaling pathways and immune cell interactions in prostate cancer. Emerging therapeutic strategies include inhibition of macrophage recruitment, modulation of macrophage polarization, cytokine-targeted therapy, immune checkpoint inhibition, and cellular immunotherapy. Reprogramming of tumor-promoting macrophages toward antitumoral phenotype has emerged as a promising area of investigation.[15]

Recent experimental studies have demonstrated encouraging results using therapies designed to alter macrophage activity within the tumor microenvironment. Combination therapies integrating androgen deprivation therapy with immune-targeted approaches may represent an important future direction in management of advanced prostate cancer. Continued exploration of inflammatory signaling pathways may facilitate development of more effective and personalized treatment strategies.[16]

Future Perspectives

Future prostate cancer research is increasingly focused on integrating molecular profiling, digital pathology, spatial transcriptomics, and immune microenvironment analysis. Advances in artificial intelligence and molecular diagnostics may further improve understanding of tumor–immune interactions and facilitate identification of novel biomarkers associated with aggressive tumor behavior. Improved characterization of immune microenvironment alterations may contribute to more accurate risk stratification, prediction of therapeutic response, and development of personalized therapeutic strategies. As understanding of inflammatory signaling pathways continues to evolve, targeting tumor-associated inflammation may become an important component of prostate cancer therapy.[17]

CONCLUSION

The tumor microenvironment plays a critical role in progression of prostate cancer through complex interactions involving inflammatory cells, stromal fibroblasts, endothelial cells, and signaling mediators. Tumor-associated macrophages represent important regulators of immune suppression, angiogenesis, extracellular matrix remodeling, and metastatic dissemination. Recent advances in molecular oncology have significantly expanded understanding of inflammatory signaling pathways and immune modulation in prostate cancer. Continued exploration of tumor microenvironment biology may facilitate development of novel biomarkers and targeted therapeutic strategies capable of improving patient outcomes.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
2. Han C, Zhang Y, Wang L, et al. The roles of tumor-associated macrophages in prostate cancer. J Oncol. 2022;2022:8570844.
3. Erlandsson A, Carlsson J, Lundholm M, et al. M2 macrophages and regulatory T cells in lethal prostate cancer. Prostate. 2019;79(4):363-369.
4. Wang J, Liu Y, Zhang X, et al. Tumor-associated macrophages and PD-L1 expression in prostate cancer. Aging (Albany NY). 2024;16(2):1451-1464.
5. Martori C, et al. Macrophages as therapeutic targets in metastatic prostate cancer. Cancers (Basel). 2022;14(15):3721.
6. Wu T, Zhao Y, Li X, et al. Crosstalk between fibroblasts and macrophages in prostate cancer microenvironment. Front Immunol. 2025;16:1452271.
7. Lo CH, Lynch CC. Multifaceted roles for macrophages in prostate cancer skeletal metastasis. Front Endocrinol (Lausanne). 2018;9:247.
8. Molina OE, LaRue H, Simonyan D, et al. High infiltration of macrophage-associated inflammatory cells predicts adverse outcomes in prostate cancer. Front Immunol. 2023;14:1198742.
9. Cui F, Xu Z, Hu J, Lv Y. Crosstalk between tumor-associated macrophages and prostate cancer cells. Front Immunol. 2022;13:991458.
10. Liu R, Zhang H, Wang T, et al. Macrophages in prostate cancer: roles in progression and therapy. J Transl Med. 2025;23(1):91.
11. Shi F, Zhang Y, Liu H, et al. Tumor-associated macrophages drive prostate cancer aggressiveness via NOTCH1 signaling. Int J Biol Sci. 2022;18(13):5125-5138.
12. Rong J, et al. Let-7b-5p inhibition promotes antitumor macrophage phenotype via SOCS1/STAT signaling. Cell Signal. 2023;104:110585.
13. Mougel A, et al. CSF-1R signaling in prostate cancer cells and macrophage interactions. Int J Mol Sci. 2022;23(11):6037.
14. Guan H, et al. Exosomal RNF157 mRNA promotes M2 macrophage polarization in prostate cancer. Front Oncol. 2022;12:1012458.
15. Xu Y, et al. PSMA-targeted CAR macrophages in prostate cancer therapy. J Hematol Oncol. 2025;18(1):42.
16. Han IH, et al. MEL-dKLA peptide reduces protumoral macrophages in prostate tumors. Front Immunol. 2025;16:1498223.
17. Kang Z, et al. Identification of macrophage signatures in prostate cancer using bioinformatics analysis. Aging (Albany NY). 2024;16(7):5832-5848.